Advertisement

Osteoporosis International

, Volume 23, Issue 9, pp 2257–2276 | Cite as

A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis

  • S. Lekamwasam
  • J. D. Adachi
  • D. Agnusdei
  • J. Bilezikian
  • S. Boonen
  • F. Borgström
  • C. Cooper
  • A. Diez Perez
  • R. Eastell
  • L. C. Hofbauer
  • J. A. Kanis
  • B. L. Langdahl
  • O. Lesnyak
  • R. Lorenc
  • E. McCloskey
  • O. D. Messina
  • N. Napoli
  • B. Obermayer-Pietsch
  • S. H. Ralston
  • P. N. Sambrook
  • S. Silverman
  • M. Sosa
  • J. Stepan
  • G. Suppan
  • D. A. Wahl
  • J. E. CompstonEmail author
  • Joint IOF-ECTS GIO Guidelines Working Group
Position Paper

Abstract

Summary

This paper provides a framework for the development of national guidelines for the management of glucocorticoid-induced osteoporosis in men and women aged 18 years and over in whom oral glucocorticoid therapy is considered for 3 months or longer.

Introduction

The need for updated guidelines for Europe and other parts of the world was recognised by the International Osteoporosis Foundation and the European Calcified Tissue Society, which set up a joint Guideline Working Group at the end of 2010.

Methods and results

The epidemiology of GIO is reviewed. Assessment of risk used a fracture probability-based approach, and intervention thresholds were based on 10-year probabilities using FRAX. The efficacy of intervention was assessed by a systematic review.

Conclusions

Guidance for glucocorticoid-induced osteoporosis is updated in the light of new treatments and methods of assessment. National guidelines derived from this resource need to be tailored within the national healthcare framework of each country.

Keywords

Bone mineral density Bone-protective therapy Fracture FRAX Glucocorticoids 

Introduction

Osteoporosis is a common complication of glucocorticoid therapy and is associated with substantial morbidity. Although awareness of the condition has grown in recent years, it remains under-diagnosed and under-treated. Glucocorticoid-induced osteoporosis (GIO) has distinct characteristics; in particular, rapid bone loss and increased fracture risk occur early after therapy is initiated, emphasising the importance of primary prevention of fracture in high-risk individuals [1].

Most currently available guidelines for the management of GIO were developed prior to the release of FRAX® and other risk assessment tools and the approval of newer pharmacological interventions for its management [2, 3, 4, 5, 6, 7, 8, 9]. In 2010, the American College of Rheumatology (ACR) revised its 2001 recommendations to incorporate advances in risk assessment and to include all currently approved treatments [10]. The need for updated guidelines for Europe and other parts of the world was recognised by the International Osteoporosis Foundation (IOF) and the European Calcified Tissue Society, which set up a joint Guideline Working Group at the end of 2010. The aim of this group was to provide a framework for the development of guidelines from which country-specific recommendations could be derived. The framework covers the management of GIO in men and women aged 18 years or over, in whom continuous oral glucocorticoid therapy at any dose is considered for 3 months or longer. All interventions approved for GIO worldwide are included, and the content will be updated at intervals.

The recommendations in this document are provided to aid management decisions for physicians in primary and secondary care but do not replace the need for physician judgement in the care of individuals in clinical practice. It is recognised that guidance will vary between countries because of differences in resources, availability and cost of treatments and health care policies.

Epidemiology of GIO

Oral glucocorticoids are prescribed for a wide variety of medical disorders, most commonly musculoskeletal disorders and obstructive pulmonary disease [11]. In a multinational population-based prospective observational study of 60,393 postmenopausal women who had visited their primary care practice within the last 2 years, the Global Longitudinal Study of Osteoporosis in Women, up to 4.6 % were currently taking oral glucocorticoids, depending on their country of origin [12].

Epidemiology of glucocorticoid-induced osteoporosis

• Up to 4.6 % of postmenopausal women are reported as currently taking oral glucocorticoids.

• Fracture risk increases during the first 3–6 months of glucocorticoid therapy and decreases following their withdrawal.

• An increase in fracture risk occurs with low doses and rises further with increasing daily dose.

• The greatest increase in risk is seen for vertebral fracture; in patients taking ≥7.5 mg/day prednisolone or its equivalent, a relative risk of 5.18 (95 % CI 4.25–6.31) has been reported.

Data from the General Practice Research Database (GPRD) in the UK have demonstrated that fracture risk is increased even with relatively low daily doses (2.5–7.5 mg) of prednisolone or its equivalent and rises further with increasing daily dose [13]. Although the cumulative dose of glucocorticoids correlates strongly with bone loss assessed by BMD measurements, the association with fracture risk is weaker than that for daily dose [14]. Increased fracture risk is seen within the first 3–6 months after starting glucocorticoids, the greatest risk being seen for vertebral fracture [15]. In patients taking ≥7.5 mg/day prednisolone or its equivalent, the relative rate of vertebral fracture was 5.18 (95 % CI 4.25–6.31), compared to 2.27 (2.16–3.10) for non-vertebral fracture. The high risk of vertebral fractures in glucocorticoid-treated patients is also emphasised by the results of a recent study in which 24 % of glucocorticoid-treated patients previously treated with alendronate or alfacalcidol developed new vertebral fractures during the 2.7-year follow-up period [16]. In a meta-analysis of data from 42,500 men and women from seven prospective cohorts followed for 176,000 patient years, previous or current glucocorticoid use was associated with a significantly increased risk of any fracture, osteoporotic fracture or hip fracture, the highest gradients of risk being seen for hip fracture. Increased fracture risk was seen at all ages from 50 years upwards and was similar in men and women [17]. Following withdrawal of glucocorticoid therapy, fracture risk decreases, consistent with the spontaneous improvement in BMD reported after successful treatment of Cushing's syndrome. A residual risk remains, possibly related to the underlying disorder for which glucocorticoids were prescribed.

Most of the available epidemiological data relate to oral glucocorticoid therapy given continuously for 3–6 months or longer. There is some evidence that high doses of inhaled glucocorticoids may be associated with reduced BMD and a small increase in fracture risk [18]. Increased fracture risk has also been reported with intermittent oral glucocorticoid therapy [19].

Pathophysiology

Glucocorticoid receptors are expressed on various extraskeletal and skeletal cells. The pathogenesis of GIO is thought to result from direct effects of exogenous glucocorticoids on bone cells and indirect effects mediated by altered calcium handling by the kidneys and the gut, reduced production of gonadal hormones and detrimental effects on the neuromuscular system, which may increase the risk of falls [20, 21].

Through activation of their high-affinity receptors, glucocorticoids modify the biology of all three major bone cells, osteoblasts, osteoclasts and osteocytes. While physiological concentrations of glucocorticoids are indispensible for differentiation of mesenchymal stromal cells into osteoblasts in vitro, exogenous glucocorticoids inhibit osteoblasts at several levels [21]. Thus, pluripotent mesenchymal stromal cells may be shifted towards the adipocytic pathway at the cost of the osteoblastic pathway when exposed to glucocorticoids [22]. The most consistent skeletal effects of glucocorticoids are to inhibit osteoblast function and to promote osteoblast apoptosis. Mechanisms involved are decreased osteoblastic production of bone anabolic factors insulin-like growth factor-1 and transforming growth factor beta, interference with the Wnt signalling pathway with upregulation of Wnt inhibitors such as Dickkopf-1 and sclerostin and alterations of the bone matrix composition by altered production of type 1 collagen and overproduction of inhibitors of matrix mineralization [20, 21, 23, 24, 25]. In addition, apoptosis of osteoblasts and osteocytes is enhanced by glucocorticoids leading to a shorter life span of bone-forming and mechanosensing cells [26]. Some of these pro-apoptotic effects of glucocorticoids may be prevented by PTH and by bisphosphonates [27, 28].

Effects on osteoclasts are somewhat controversial and may involve both osteoblast-mediated and direct actions [20, 21]. Glucocorticoids upregulate the ratio of receptor activator of NF-κB ligand (RANKL) to osteoprotegerin by osteoblasts, most likely as a direct consequence of suppressed osteoblast differentiation, which translates into increased osteoclastogenesis [29, 30]. Glucocorticoids also interfere with the ruffled border of the osteoclast; in addition, mice with a targeted deletion of the osteoclastic glucocorticoid receptor were protected against suppression of bone formation following glucocorticoid exposure, indicating that glucocorticoids signal through the osteoclast to modulate osteoblast function [31]. It should be noted that these concepts of pathogenesis are predominantly based on observations made in preclinical models and have not been validated in humans.

Methods and search strategy

Systematic search

The systematic search published in the ACR guidelines was updated to include the period of 1 April 2009 to 31 December 2010. The systematic search for clinical trials in patients taking oral glucocorticoids was conducted in MEDLINE through PubMed using the search terms described below. Only the approved therapeutic agents agreed by the panel, etidronate, alendronate, risedronate, zoledronic acid, vitamin D2 and D3, alfacalcidol, calcitriol, calcium, teriparatide and PTH, were included in the search. In MEDLINE, both Free Text and MeSH search options were used. A similar search was performed in the Cochrane Trial Registry (CENTRAL) to ensure the completeness of the search. Furthermore, the Clinical Queries option (with the Broader and Sensitive filter) of PubMed was searched to capture systematic reviews and randomized controlled trials (RCTs). The PubMed search was limited to RCTs, controlled clinical trials, systematic surveys and meta-analysis, age (18 years or over) and publications in the English language. Only studies with information on BMD and/or fracture and with a minimum follow-up period of 6 months were included. Studies involving transplant recipients were excluded. Ninety-four articles were identified by the MEDLINE search, of which seven met the criteria for inclusion. Eleven further articles were identified by the CENTRAL search of which one met the inclusion criteria (see Table 1, Appendix; Archives of Osteoporosis DOI  10.1007/s11657-012-0070-7).

Quality rating of studies

The quality of published studies was assessed using the Jadad score [32]. Studies were assessed independently by three members of the working group, and the scores were averaged (Table 1, Appendix; Archives of Osteoporosis DOI  10.1007/s11657-012-0070-7).

Hand search of abstracts

Meeting abstracts from 1 April 2009 to 31 Dec 2010 were hand searched. Abstracts of the annual meetings of the American College of Rheumatology, International Osteoporosis Foundation-European Congress on Clinical and Economic Aspects of Osteoporosis, the European League Against Rheumatism, American Society for Bone and Mineral Research, and European Calcified Tissue Society were searched for clinical trials that met the criteria described above. The search identified eight abstracts.

Grading of recommendations

The grading of recommendations was derived as follows:

Level of grade of evidence/type of evidence recommendation

  1. Ia.

    Meta-analysis of RCTs/A

     
  2. Ib.

    At least one RCT/A

     
  3. IIa.

    At least one well-designed, controlled study but without randomization/B

     
  4. IIb.

    At least one well-designed, quasi-experimental study/B

     
  5. III.

    At least one well-designed, non-experimental descriptive study (e.g. comparative studies, correlation studies, case studies)/B

     
  6. IV.

    Expert committee reports, opinions and/or experience of respected authorities/C

     

Assessment of fracture risk

FRAX® is a computer-based algorithm (http://www.shef.ac.uk/FRAX) that calculates the 10-year probability of a major fracture (hip, clinical spine, humerus or wrist fracture) and the 10-year probability of hip fracture [33, 34, 35, 36].

Fracture probability differs markedly in different regions of the world [37] so that FRAX is calibrated to those countries where the epidemiology of fracture and death is known (currently 40 countries). It is the recommended method of risk assessment in an increasing number of guidelines [10, 11, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48].

Assessment of risk

A general approach to risk assessment is shown in Fig. 1 [45]. The management process begins with the assessment of fracture probability and the categorization of fracture risk on the basis of age, sex, body mass index (BMI) and clinical risk factors. On this information alone, some patients at high risk may be offered treatment without recourse to BMD testing. There will be other instances where the probability is so low that a decision not to treat can be made without BMD. The size of the intermediate category in Fig. 1 will vary in different countries. In countries that provide reimbursement for DXA, this will be a large category, whereas in a large number of other countries with limited or no access to densitometry, the size of the intermediate group will necessarily be small. In other countries (e.g. the UK), where provision for BMD testing is sub-optimal [49], the intermediate category will lie between the two extremes. The rationale for the use of FRAX in the absence of access to BMD or limited access has been recently reviewed [50].
Fig. 1

Management algorithm for the assessment of individuals at risk of fracture [45]. CRFs clinical risk factors

FRAX adjustment for dose of oral glucocorticoids

One of the limitations of FRAX is that use of oral glucocorticoids is entered as a dichotomous risk factor (yes/no) and does not take into account the dose of glucocorticoids. Neither does it accommodate the duration of use, except that exposures of less than 3 months should not be entered [51]. For longer-term use, FRAX assumes an average risk, providing hazard ratios for an average dose and duration of exposure to glucocorticoids [17]. As expected, higher-than-average daily doses of oral glucocorticoids (2.5–7.5 mg prednisolone or its equivalent) are associated with higher risks of fracture while lower-than-average doses are associated with lower risks [15, 52, 53].

Use of FRAX in glucocorticoid-induced osteoporosis

• Oral glucocorticoid use is entered into FRAX as a dichotomous risk factor and does not take into account the daily dose or duration of use.

• FRAX assumes an average dose of prednisolone (2.5–7.5 mg/day or its equivalent) and may underestimate fracture risk in patients taking higher doses and overestimate risk in those taking lower doses.

• Using UK data, the average adjustments over all ages in postmenopausal women and men aged ≥50 years are 0.65 for daily doses <2.5 mg/day prednisolone or its equivalent and 1.20 for daily doses ≥7.5 mg/day prednisolone or its equivalent for hip fracture, and 0.8 and 1.15, respectively, for major osteoporotic fracture.

• For high doses of glucocorticoids, greater upward adjustment of fracture probability may be required.

Under certain assumptions, relatively simple arithmetic procedures have been formulated which can be applied to conventional FRAX estimates of probabilities of hip fracture and a major osteoporotic fracture to adjust the probability assessment with knowledge of the dose of glucocorticoids (Table 1) [54]. For example, a woman aged 60 years from the UK taking glucocorticoids for rheumatoid arthritis (no other risk factors and BMI of 24 kg/m2) has a 10-year probability for a major fracture of 13 %. If she is on a higher-than-average dose of prednisolone (>7.5 mg daily or its equivalent), then the revised probability should be 15 % (13 × 1.15).
Table 1

Average adjustment of 10-year probabilities of a hip fracture or a major osteoporotic fracture in postmenopausal women and older men according to dose of glucocorticoids

Dose

Prednisolone equivalent (mg/d)

Average adjustment over all ages

Hip fracture

Low

<2.5

0.65

Medium

2.5–7.5

No adjustment

High

≥7.5

1.20

Major osteoporotic fracture

Low

<2.5

0.8

Medium

2.5–7.5

No adjustment

High

≥7.5

1.15

Adapted from [54], with kind permission from Springer Science+ Business Media B.V.

For higher doses of prednisolone, greater upward adjustment of fracture probability may be required. Data from the GPRD indicate that in patients with a daily dose of 20 mg/day of prednisolone or its equivalent, the excess risk of non-vertebral fracture was increased approximately threefold compared to those taking ≤5 mg/day or its equivalent [53] and that this risk increases further with even higher doses.

The same principles apply to other risk factors used in FRAX in that probability assessments need to be tempered by ancillary information of clinical relevance [55]. Examples include a high falls risk, multiple prior fractures, immobility and severe rheumatoid arthritis. Since spine BMD cannot be entered into FRAX, fracture risk might be underestimated in individuals in whom BMD is substantially lower in the spine than in the hip. A simple procedure has been described to incorporate the offset between spine and hip BMD in such cases that enhances prediction of both vertebral and major osteoporotic fracture risk [56]. In addition, clinical, but not morphometric, vertebral fractures are included in the major osteoporotic probabilities generated by FRAX, and the risk of all vertebral fractures may be underestimated.

Intervention thresholds

Recommendations for intervention thresholds in GIO are contentious and have a weaker evidence base than in postmenopausal osteoporosis. The revised ACR guidelines recommend treatment in postmenopausal women and men aged 50 years or older starting on oral glucocorticoids with a FRAX-derived 10-year probability of major osteoporotic fracture of over 10 % and in those with a probability of less than 10 % if the daily dose of prednisolone or its equivalent is ≥7.5 mg/day. The threshold of >10 % in patients taking ≥7.5 mg/day is considerably lower than that used in postmenopausal osteoporosis (20 %) [10].

National guidelines for the management of GIO have been published in some other countries including Canada, Belgium, France, Japan, Italy, Spain and the UK [5, 40, 48, 57, 58, 59, 60], but in many countries, national guidelines are not available. Approaches used to set intervention thresholds depend critically on local factors such as reimbursement policies, health economic assessment, willingness to pay for health care in osteoporosis and access to DXA [10, 11, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 61, 62]. For this reason, it is not possible or desirable to recommend a unified intervention strategy.

In non-glucocorticoid-treated postmenopausal women with osteoporosis, most guidelines recommend that women with a prior fragility fracture may be considered for intervention without the necessity for a BMD test (other than to monitor treatment) [3, 10, 44, 48, 63, 64, 65]. In the UK, the intervention threshold in women without a prior fracture is set at the age-specific fracture probability equivalent to women with a prior fragility fracture [40] and therefore rises with age. Using this criterion, intervention thresholds will vary from country to country because the population risks of fracture and death vary [37, 66] (Table 2).
Table 2

Examples of intervention thresholds (equivalent to the age-specific fracture probability in women with prior fragility fracture) as set by FRAX-based 10-year probability (in percent) of a major osteoporotic fracture in postmenopausal women with a previous fracture (no glucocorticoid treatment or other clinical risk factors, a body mass index of 24 kg/m2 and without BMD) [66]

Age

Germany

UK

Spain

France

Italy

50–55

7.1

8.2

3.7

5.5

7.4

55–60

7.8

10.6

4.6

6.3

8.5

60–65

10.2

14.0

6.2

8.0

11.2

65–70

13.9

18.2

9.0

11.1

15.1

70–75

18.1

21.6

12.6

15.8

18.9

75–80

23.2

25.3

18.0

22.2

23.9

80–85

28.9

30.1

23.5

30.4

29.9

85+

30.6

33.2

23.6

36.0

31.5

An example of a strategy that has been adopted in the UK is given below. It is similar to strategies commonly applied in Europe in the context of postmenopausal osteoporosis, but takes into account the marked variations in access to DXA in different European countries [49]. The approach, originally applied by the National Osteoporosis Guideline Group (NOGG) in the UK, has been validated [67, 68, 69, 70, 71, 72].
  • If no access to DXA is available, assessment of fracture probability is determined using FRAX and treatment considered for those in whom fracture probability lies above the intervention threshold.

  • If access to DXA is available, the use of FRAX demands not only consideration of the fracture probability at which to intervene (intervention threshold) but also the fracture probability for BMD testing (assessment thresholds) [40, 45]. Assessment thresholds for the UK are shown in Fig. 2.
    Fig. 2

    Assessment guidelines of the UK National Osteoporosis Guideline Group based on the 10-year probability of a major fracture (in percent). The dotted line denotes the intervention threshold. Where assessment is made in the absence of BMD, a BMD test is recommended for individuals where the probability assessment lies in the mid-region. Adapted from [45]

  • If access to DXA is limited, those with fracture probabilities above the lower assessment threshold but below the upper assessment threshold can be considered for BMD testing and their fracture probability reassessed. Treatment can then be considered in those with a fracture probability above the intervention threshold.

  • If unlimited access to DXA is available, all those with fracture probabilities above the lower assessment threshold can be considered for BMD testing and their fracture probability reassessed. Treatment can then be considered in those with a fracture probability above the intervention threshold.

Clinical scenarios for glucocorticoid-induced osteoporosis in the UK

Table 3 shows several clinical scenarios applied to the assessment strategy of NOGG (limited access to BMD). At an intervention threshold of around 20 %, the majority of patients aged ≥70 years and/or with a previous fracture would be considered eligible for treatment. In addition, those aged 50–70 years who are on high doses of glucocorticoids could be considered eligible for treatment, depending on the dose and other clinical risk factors. In the remaining situations, a T-score of approximately −1.5 or lower is required. Similar recommendations are made for men, since the effectiveness and cost-effectiveness of intervention in men with osteoporosis are broadly similar to those of postmenopausal osteoporosis for an equivalent risk [73, 74]. These recommendations make the plausible but untested assumption that the independent contribution to fracture risk of most diseases for which glucocorticoid therapy is prescribed is similar to that of rheumatoid arthritis.

Indications for bone-protective therapy in postmenopausal women and men ≥50 years on glucocorticoid therapy

• Aged ≥70 years

• Previous fragility fracture or incident fragility fracture during glucocorticoid therapy

• High doses of glucocorticoids, depending on daily dose and presence or absence of other clinical risk factors

• BMD T-score ≤−1.5

Table 3

Clinical scenarios for women in the UK (BMI = 24 kg/m2) showing the 10-year probability of a major fracture by age for a high dose of glucocorticoids (GC) (>7.5 mg/day) using the adjustment factor [54], an average dose of glucocorticoids (2.5–7.5 mg/day) in a woman with rheumatoid arthritis (RA), and an average dose of glucocorticoids with a prior fracture (Fx)

Age (years)

High-dose GC

GC + RA

GC + Fx

50

6.7 (−1.5)a

7.6 (−1.4)a

12b

55

8.9 (−1.5)a

10 (−1.4)a

15b

60

11 (−1.7)a

13 (−1.4)a

20b

65

16 (−1.7)a

19 (−1.4)a

26b

70

21b

24b

31b

75

24b

30b

35b

80

29b

36b

39b

85

33b

41b

43b

90

34b

42b

43b

The numbers in parentheses represent the approximate T-scores at which the probability would lie at or above the NOGG intervention threshold (FRAX version 3.4 for the UK)

aRecommended BMD test

bRecommended treatment

Investigations

A full clinical history should be taken, including details of co-morbidity, glucocorticoid use (previous or ongoing, dosage, duration and route of administration), fracture history (type and trauma), alcohol intake, smoking, height loss, family history of osteoporosis and hip fracture. The history should include an assessment of dietary calcium intake, obtained either informally or using a food frequency questionnaire. Height and weight should be measured. Routine biochemical testing should be performed to exclude causes of secondary osteoporosis other than glucocorticoid use including assessment of vitamin D status and renal function (Table 4). Measurement of BMD by DXA at the spine and hip is generally recommended. Lateral imaging DXA with vertebral fracture assessment (VFA) is of value in detecting existing vertebral fractures [75], but if this is not available, lateral X-rays of the thoracic and lumbar spine should be considered in patients with back pain, documented loss of height or kyphosis, or low BMD.
Table 4

Investigations to exclude causes of secondary osteoporosis

Investigation

Reason

Full blood count and ESR

Exclude anaemia; high ESR may suggest monoclonal gammopathy

Creatinine, urea, eGFR

Exclude chronic kidney disease

Calcium, phosphate, alkaline phosphatase, albumin

Exclude primary hyperparathyroidism, malignancy, osteomalacia, Paget's disease

Liver function tests

Exclude chronic liver disease, alcohol abuse

Oestrogen, testosterone, LH, FSH

Exclude hypogonadisma

IgA anti-tissue transglutaminase antibody or IgA endomysial antibody

Exclude coeliac disease

Immunoglobulins, Bence Jones Protein, serum free light chains

Exclude monoclonal gammopathy

Serum 25OHD

Exclude vitamin D deficiency

Serum TSH

Exclude hyperthyroidism

aNot required in women who are known to be postmenopausal

Management of glucocorticoid-induced osteoporosis (Figs. 3 and 4)

General measures in the management of GIO

Certain general measures can be advocated in individuals taking glucocorticoids, although the evidence base for their effects on fracture risk is weak (Table 5). The dose of glucocorticoids should be regularly reviewed and kept to a minimum. Alternative routes of administration (e.g. topical, inhaled) or formulations (e.g. budesonide) may be considered, and in some situations, use of alternative immunosuppressive agents may enable reduction in the dose of glucocorticoids. Adequate levels of dietary calcium intake, good nutrition and maintenance of a normal body weight should be encouraged. Tobacco use and alcohol abuse should be avoided, and appropriate levels of physical exercise should be encouraged. Falls risk assessment and, where appropriate, advice to reduce the risk of falls should be performed in those at increased risk of falling.
Table 5

General measures in the management of GIO

Recommendation

Level of evidence

Reduce dose of glucocorticoid when possible

C

Consider glucocorticoid-sparing therapy

C

Consider alternative route of glucocorticoid administration

C

Advise good nutrition especially with calcium and vitamin D

C

Regular weight-bearing exercise

C

Avoid tobacco use and alcohol abuse

C

Assess falls risk and give advice if appropriate

C

Fig. 3

Postmenopausal women and men aged ≥50 years

Fig. 4

Premenopausal women and men aged ≤50 years

Pharmacological interventions

Although a number of interventions have been evaluated in the management of GIO, the strength of evidence for their efficacy is weaker than that for postmenopausal osteoporosis, since fracture reduction has not been a primary end point of any study. This reflects the acceptance by regulatory authorities of bridging studies, using BMD, for agents proposed for GIO that have been shown to reduce fractures in postmenopausal osteoporosis [76]. Fracture data in GIO studies are therefore only available as secondary end points or as safety data. Studies in GIO are limited further by their short duration and heterogeneity of trial populations with respect to age, sex, underlying disease, co-morbidities, concurrent medications and the variable timing of intervention in relation to initiation of glucocorticoid therapy. In addition, the number of men and premenopausal women in these studies has generally been low, so the evidence for treatment of these other groups is weak.

Pharmacological interventions in glucocorticoid-induced osteoporosis

• Bone-protective treatment should be started at the onset of glucocorticoid therapy in patients at increased risk of fracture.

• Alendronate, etidronate, risedronate, zoledronic acid and teriparatide are the front-line therapeutic options for the majority of patients.

• If glucocorticoid therapy is stopped, withdrawal of bone-protective therapy may be considered, but if glucocorticoids are continued long term, bone protection should be maintained.

• Adequate calcium intake should be achieved through dietary intake if possible, with the use of supplements if necessary.

• An adequate vitamin D status should be maintained, using supplements if required.

Table 6 summarizes the grading of recommendation for pharmacological interventions approved for management of GIO. For the bisphosphonates, alendronate [77, 78, 79, 80, 81], etidronate [82, 83, 84, 85, 86, 87, 88, 89, 90, 91], risedronate [92, 93, 94, 95, 96] and zoledronic acid [97], and for the osteoanabolic, teriparatide, there is good evidence from placebo-controlled or comparator studies of beneficial effects on spine and hip BMD [98, 99]. The wording of the indication for GIO varies between countries, but in EU countries, no distinction is made between prevention and treatment.
Table 6

Grading of evidence for pharmacological interventions used in the management of GIO

Intervention

Spine BMD

Hip BMD

Vertebral fracture

Non-vertebral fracture

Alendronate

A

A

Bc

nae

Etidronate

A

A

Ac

nae

Risedronate

A

A

Ac

nae

Zoledronic acid

Aa

Aa

nae

nae

Teriparatide

Aa

Aa

Aa,c

nae

Alfacalcidol

A

Ab

nae

nae

Calcitriol

A

Ab

nae

nae

nae not adequately evaluated

aComparator study

bData inconsistent

cNot a primary end point

In the case of alfacalcidol [78, 100, 101, 102, 103, 104] and calcitriol [105, 106], similar evidence exists for spine BMD, but data for effects on hip BMD are inconsistent. Evidence for vertebral fracture reduction, albeit not as a primary end point, was reported in placebo-controlled or comparator studies for alendronate [77], etidronate [82], risedronate [96] and teriparatide [98, 99]. The lower grading for alendronate reflects the omission, in the extension study, of patients who had fractured during the first year of the study. No data are available for non-vertebral fractures or hip fractures.

Since no treatment studies were designed to demonstrate fracture reduction and, with the exception of four studies [78, 97, 98, 99, 103], there are no head-to-head comparisons of interventions, inferences about the relative efficacy of different treatments cannot be made. In the comparator studies, superiority of BMD change was shown for zoledronic acid over risedronate [97]. Teriparatide was significantly more effective than alendronate in increasing BMD and in reducing vertebral fracture, although the latter was not a primary end point [98, 99]. The weaker evidence for alfacalcidol and calcitriol with respect to changes in hip BMD helps to establish bisphosphonates and teriparatide as the front-line options for the majority of patients. In clinical practice, the choice of treatment in individual patients will be mainly influenced by cost and tolerability.

Because rapid bone loss and increased fracture risk occur soon after the initiation of glucocorticoid treatment, bone-protective therapy should be started at the onset of glucocorticoid therapy in individuals at increased risk of fracture. If glucocorticoid therapy is subsequently stopped, withdrawal of bone protection may be considered with reassessment of fracture risk, preferably including a measurement of BMD. In those who continue to take glucocorticoids long term, treatment should be continued. In patients treated with teriparatide, anti-resorptive therapy should be considered following the permitted treatment duration of 24 months [107].

Calcium and vitamin D

Because glucocorticoid therapy is associated with reduced intestinal and renal calcium absorption and increased urinary calcium excretion, increasing calcium intake seems a logical approach [108]. However, in most studies in which calcium alone served as the control therapy, bone loss was not prevented by calcium supplementation. For instance, despite a daily dose of 500 mg [92], 800 mg [109] or even 1,000 mg [110] of calcium, lumbar spine BMD continued to decline in patients on at least 7.5 mg/day of prednisone (by 2.8, 4.6 and 4.3 % over 12 months, respectively). These findings suggest that calcium alone may not be sufficient to prevent glucocorticoid-induced bone loss [111].

Calcium supplementation should be combined with vitamin D as patients on glucocorticoids commonly have vitamin D insufficiency [112]. Combined calcium and vitamin D supplementation—either native vitamin D [113] or activated vitamin D metabolites [101]—was more effective in preserving BMD than either calcium alone or no therapy. In a 2-year randomized trial in patients with rheumatoid arthritis receiving a mean daily dose of 5.6 mg prednisone, patients on 1,000 mg calcium and 500 IU (12.5 μg) vitamin D3 daily had significant gains in BMD (0.7 and 0.9 % per year at the spine and hip, respectively), while those on placebo lost BMD (at a yearly rate of 2.0 and 0.9 %, respectively) [114]. Similarly, in a 1-year randomized trial, patients receiving high doses of glucocorticoids (prednisone ≥30 mg per day) gained lumbar spine BMD 0.39 % over 1 year when randomized to calcium 405 mg plus alfacalcidol 1 μg daily. In contrast, patients randomized to calcium alone lost BMD at a rate of 5.7 % [101].

Two meta-analyses have confirmed the beneficial effect of combined calcium and vitamin D in the prevention of glucocorticoid-induced osteoporosis. In these analyses, both trials with calcium and native vitamin D and with calcium and active vitamin D metabolites were included and compared with calcium alone or placebo [114, 115]. Both analyses showed a beneficial effect of combination therapy on BMD. In contrast, other outcomes including fracture incidence were not significantly affected. There is no evidence that active vitamin D metabolites are more effective than native vitamin D (cholecalciferol, vitamin D3) in preventing bone loss or fractures in glucocorticoid-treated patients [103, 116]. However, the risk of developing hypercalcaemia and hypercalciuria is higher with active metabolites.

Based on the available evidence, current UK guidelines recommend an adequate calcium and vitamin D intake to all individuals on glucocorticoids for three or more months [3]. Similarly, the updated recommendations from the American College of Rheumatology recommend a total daily calcium intake of 1,200 to 1,500 mg with 800 to 1,000 IU (20–25 μg) vitamin D for all patients starting glucocorticoid therapy [11]. Although some recent studies have suggested an association between use of calcium and vitamin D supplementation and risk of cardiovascular disease, this remains controversial [117, 118]. Where possible, dietary means should be used to achieve an adequate intake of calcium and the use of supplements reserved for individuals with low intakes.

Cost-effectiveness of the treatment of GIO

Although the cost-effectiveness of treatments for osteoporosis has been assessed in a number of studies [119, 120], few have specifically addressed GIO [73, 121, 122, 123, 124]. However, if the assumption is made that drugs provide similar efficacy and safety in GIO as observed for postmenopausal osteoporosis [73], cost-effectiveness estimates for PMO can be transferred to GIO at equivalent fracture risk.

A pan-European study from 2004 estimated the cost-effectiveness of branded alendronate in nine countries in non-glucocorticoid-treated postmenopausal women [125]. In this study, alendronate was shown to be cost saving compared to no treatment in women with osteoporosis (with and without previous vertebral fracture) from the Nordic countries (Norway, Sweden and Denmark). The cost-effectiveness of alendronate compared to no treatment was also within acceptable ranges in Belgium, France, Germany, Italy, Spain and the UK. However, with the decreased price of generic alendronate, analyses based on a branded drug price have become obsolete and would require an update.

In a study from the UK by Kanis et al. [71], generic alendronate was shown to be cost effective in the prevention and treatment of fractures in postmenopausal women with a 10-year fracture probability for a major fracture that exceeded 7.5 %. Thus, the treatment scenarios envisaged by NOGG can be considered as cost effective (Table 3). Other drugs that are approved for GIO (risedronate, teriparatide and zoledronic acid) are associated with higher cost-effectiveness ratios compared to no treatment mainly due to their higher price. A recent study by Borgström et al. [126], again conducted in a UK setting, showed that risedronate was cost effective above a 10-year probability of 13 % for a major osteoporotic fracture. However, the cost-effectiveness of different interventions will vary between countries due to differences in drug costs, fracture risk, costs of treating fractures, utility estimates and willingness to pay.

Safety of treatments in GIO

Treatment studies in GIO have generally been smaller and of shorter duration than those in postmenopausal osteoporosis so that information on adverse effects, particularly those occurring with long-term treatment, is relatively sparse. Adverse events might be expected to occur more frequently in glucocorticoid-treated individuals because of co-morbidities and co-medications. However, there is no positive evidence to indicate that the safety profile of bisphosphonates and other drugs used in GIO differs significantly from that observed in women treated for postmenopausal osteoporosis.

Atypical femoral fractures

Recently, concerns have arisen about a possible association between bisphosphonate use and atypical subtrochanteric and femoral shaft fractures (AFFs) [127, 128]. These fractures are rare, comprising approximately 1 % of all hip and femoral fractures [129], but carry a high morbidity. Although epidemiological studies have reported conflicting results on whether bisphosphonate therapy is associated with increased risk of AFFs, several recent studies indicate an association between duration of bisphosphonate use and the incidence of AFFs [130, 131, 132]. Glucocorticoids have been proposed as a risk factor for the development of AFFs in a number of studies [129, 133, 134, 135, 136, 137, 138, 139], although in a recent case control study in which atypical fractures were confirmed radiologically, the use of glucocorticoids was not associated with increased risk of AFFs in patients who were taking bisphosphonates [131].

A causal association between bisphosphonate use and AFFs and the possible role of glucocorticoids in the pathogenesis of these fractures remain to be firmly established. Nevertheless, imaging should be considered in patients taking bisphosphonates who develop unexplained thigh or groin pain. In view of the rare occurrence of AFFs and the proven efficacy of bisphosphonates, the overall benefit/risk balance of bisphosphonate therapy is strongly positive in glucocorticoid-treated patients who are at increased risk of fracture.

Osteonecrosis of the jaw

An increased risk of osteonecrosis of the jaw (ONJ) has been reported in patients treated with bisphosphonates, particularly in those exposed to high doses of bisphosphonates for treatment of skeletal malignancy. In patients treated with the lower doses used for osteoporosis, however, the incidence of ONJ is very low (between 1/10,000 and 1/100,000 person exposure years) [140, 141]. Although glucocorticoid therapy has been reported in some cases of bisphosphonate-associated ONJ, there is no evidence that ONJ is more common in bisphosphonate-treated patients taking glucocorticoids than in those treated with bisphosphonates alone [142, 143, 144].

In patients receiving treatment for GIO who are at increased risk of fracture, therefore, the benefit/risk balance of bisphosphonate therapy is strongly positive. However, because of the well-established role of dental disease and trauma in the pathogenesis of ONJ, where possible, invasive dental procedures should be avoided in patients taking bisphosphonates, and pre-existing severe dental disease should be treated prior to initiation of bisphosphonate therapy. In addition, patients should be instructed to maintain good oral health.

Bisphosphonates and pregnancy

The use of bisphosphonates in women of childbearing age raises potential concerns about fetal safety because of the long half-life of bisphosphonates in bone and their ability to cross the maternal placenta. In animal models, high doses of bisphosphonates cause fetal underdevelopment and skeletal retardation [145]. However, data in humans are available only from sporadic clinical cases, and no systematic studies have been conducted. A review of the scientific literature evaluated a total of 58 women treated with bisphosphonates just before or during pregnancy and found no evidence of abnormalities in the offspring [146]. Two cohort studies analysing pregnancy outcomes in women treated with bisphosphonates up to the third month of pregnancy reported no obvious excess of adverse fetal outcomes, although one case of Apert's syndrome (an autosomal dominant condition associated with a fibroblast growth factor 2 mutation causing acrocephalosyndactyly) occurred in a woman exposed to bisphosphonates [147, 148].

Although overall these data are reassuring, bisphosphonates should be avoided in premenopausal women, most of whom have a low absolute risk of fracture, unless there are strong indications for treatment (see Section 14).

Monitoring

The goal of bone-protective therapy in glucocorticoid-treated individuals is to reduce the risk of fractures. Minimal follow-up includes verification that the patient is taking the medication, that the dosing procedure for the drug is appropriate and that the patient is taking sufficient calcium and vitamin D. During follow-up, a careful assessment of new fractures should be included; rib and vertebral fractures are particularly common in GIO. Annual height measurements should be included in the monitoring visit, and spine radiographs or vertebral fracture assessment (VFA) by DXA should be obtained if there has been significant height loss (more than 2 cm) or if there are other symptoms or signs that raise suspicion of fracture (note that vertebral fractures are often asymptomatic in GIO) (Table 7). However, the incidence of fragility fractures on treatment is low, and absence of fracture during treatment does not necessarily mean treatment is effective. Therefore, surrogate indices of treatment efficacy are recommended.
Table 7

Recommendations for monitoring during glucocorticoid therapy

Recommendation

Grading of evidence

Assessment of adherence to therapy, including calcium and vitamin D, at each visit

C

Measurement of BMD at appropriate intervals

C

Annual height measurement

C

Vertebral fracture assessment by X-ray or DXA if fracture is suspected

C

Measurement of serum PINP after 3 months of teriparatide therapy

C

In glucocorticoid-treated patients not receiving bone-protective therapy, BMD measurements using DXA are recommended at baseline and at appropriate intervals thereafter depending on the baseline level, the dose of GC, the disease for which it is given and the age and gender of the patient. In patients receiving bone-protective therapy, monitoring with BMD is recommended, the frequency of which will depend on the same factors. The BMD measurement precision error (the least significant change at each skeletal site established for the laboratory) must be considered when interpreting serial assessments in order to determine whether the change is real [149, 150, 151]. However, it should be emphasised that improvement in BMD during treatment with anti-resorptive drugs accounts for a predictable but small part of the observed reduction in the risk of vertebral fracture in postmenopausal osteoporosis [152], and the relationship between BMD changes and fracture risk reduction in patients treated for glucocorticoid-induced osteoporosis is unknown. Poor adherence to therapy, failure to respond to therapy or previously unrecognised secondary causes of osteoporosis should be searched for in patients with documented BMD loss [153, 154, 155].

In postmenopausal osteoporosis, there is growing evidence that biochemical markers have potential value in monitoring the response to treatment [156]; their use in monitoring treatment in glucocorticoid-treated patients is less well established but is an important area for future research. Absence of an increase in serum PINP after 3 months of teriparatide may identify patients in whom adherence is sub-optimal [157]. It should be noted that the underlying disease may itself affect bone turnover markers (BTMs), and the relationship between changes in BTMs and fracture risk has not been evaluated in GIO.

Management of GIO in younger men and premenopausal women

Younger men (≤50 years)

There are very few data on the use of glucocorticoids in younger men. In the reported randomized double-blind trials, the majority of men were over the age of 50 years, with none of the trials reporting on subsets of younger men. As such, any recommendations that can be made are based on expert opinion. In men, therapy with a bisphosphonate is of benefit when compared to placebo in maintaining bone mass. No conclusions may be drawn regarding reduction in fracture risks.

Premenopausal women

In general, premenopausal women on glucocorticoids are less susceptible to fracture than postmenopausal women. However, a small study suggested that glucocorticoid-treated premenopausal women fractured at higher BMD than their postmenopausal counterparts [158]. Vertebral fractures in premenopausal women treated with glucocorticoids may be associated with lower cortical bone mass than in those without a fracture [159]. Independently of BMD, elevated BTMs might identify cases with prevalent vertebral fracture [160]. Factors other than glucocorticoids that help to identify premenopausal women at increased fracture risk are prior fractures [161, 162], low BMD [163], family history of osteoporosis [164, 165, 166, 167], low BMI or low weight [168, 169], age [170, 171], age at menarche [164, 169], major depression [172] and alcohol intake [170]. In those on glucocorticoids, sustained high doses may increase the risk of fracture [170].

Management of glucocorticoid-induced osteoporosis in premenopausal women and men aged 50 years or less

• Premenopausal women and younger men have a lower risk of fracture than older individuals.

• Data on the effects of pharmacological interventions in this population are sparse, particularly with regard to fracture risk.

• Bone-protective therapy may be appropriate in some premenopausal women and younger men, particularly in individuals with a previous history of fracture or receiving high doses of glucocorticoids.

• Caution is advised in the use of bisphosphonates in women of childbearing age.

Men and premenopausal women on oral glucocorticoids are less likely to undergo BMD testing and to receive bone-protective therapy than postmenopausal women [173], possibly because indications for the prevention of bone loss and fractures are not as clearly defined as in postmenopausal women. There are a few treatment studies that are confined to premenopausal women; however, in general, the studies that have been done include premenopausal women as a subset of the overall study, and there are very few fracture data from which conclusions may be drawn. As a result, the available evidence is based on BMD data.

In large randomized controlled trials in which subsets of premenopausal women and men were studied, therapy with alendronate [79], risedronate [92] and etidronate [82] has been reported to prevent bone loss at the lumbar spine when compared to placebo. In the comparative study of zoledronic acid versus risedronate [98], a subset analysis of men in the trial demonstrated significantly greater increases in lumbar spine BMD at 1 year in men treated with zoledronic acid than in those treated with risedronate, both in the prevention and treatment subpopulations. Total hip BMD increased significantly in men treated with zoledronic acid, although the treatment difference was not significantly greater than that seen in risedronate-treated men [103]. In a post hoc analysis in premenopausal women included in this trial, significantly greater increases in total hip, but not lumbar spine, BMD were seen at 12 months in women treated with zoledronic acid when compared with those treated with risedronate [174].

Teriparatide has been shown to result in larger increases in BMD than alendronate in premenopausal women and men with GIO [175]. Radiographic vertebral fractures were not seen in any premenopausal women or men treated with teriparatide and were present in four men, but no premenopausal women, treated with alendronate. Non-vertebral fractures occurred in two premenopausal women and one man treated with teriparatide and two men, but no premenopausal women, treated with alendronate. In comparison, radiographic vertebral fractures were seen in one and six postmenopausal women treated with teriparatide and alendronate, respectively, with corresponding figures for non-vertebral fracture of nine and six [175]. However, fracture was not a primary end point of this study, and the small number of fractures in premenopausal women and younger men precludes any conclusions about the relative anti-fracture efficacy of alendronate and teriparatide in these populations.

In studies limited to premenopausal women, alendronate was more effective in maintaining BMD compared to either calcitriol [176] or alfacalcidol [177]. Etidronate was also found to be more effective at preventing bone loss than alfacalcidol in premenopausal women treated with glucocorticoids [178, 179, 180]. In patients with systemic lupus erythematosus (SLE) treated with high-dose glucocorticoids, of whom 70 % of women were premenopausal, risedronate was of benefit in preventing bone loss at the lumbar spine [181]. In a study of glucocorticoid-treated patients with chronic kidney disease in which women in the study were predominantly premenopausal, risedronate was effective in preventing bone loss at the lumbar spine when compared to active vitamin D [182]. In another small study of predominantly premenopausal women with renal disease, the combination of risedronate and alfacalcidol appeared to be of greater benefit than either alone [183]. In studies limited to calcitriol compared to calcium and vitamin D [184] and vitamin D compared to placebo [185], no significant benefit of calcitriol over calcium and vitamin D or vitamin D over placebo was demonstrated. In a small study of inhaled and intermittent oral glucocorticoids, which did contain premenopausal women, calcitriol did not offer any benefit over placebo [186].

In a small study of hypogonadal women with SLE, hormone replacement therapy was more effective than calcitriol in preventing bone loss [187]. In another small study of alfacalcidol compared to placebo [100], alfacalcidol was of benefit in maintaining bone mass.

Despite the lack of evidence for fracture reduction in glucocorticoid-treated premenopausal women, bone-protective therapy may be appropriate in some cases, particularly in patients treated with high doses of glucocorticoids and in those with a previous history of fracture. Long-term use of bisphosphonates and the potential for side effects remain a concern. Caution is advised to women of childbearing age as bisphosphonates cross the placenta and may affect the skeletal health of the developing fetus (see Section 12).

Notes

Acknowledgments

We are grateful to Amanda Sherwood and Heidi-Mai Warren from the European Calcified Tissue Society and Judy Stenmark from the International Osteoporosis Foundation, for administrative support. This paper has been consulted by the IOF Committee of National Societies and the following associations: EFFORT, AO Trauma, International Society of Orthopaedic Surgery and Traumatology, Endocrine Society, International Society of Endocrinology, AACE, ILAR, EULAR, ACR, International Menopause Society, International Association of Gerontology and Geriatrics, European Union Geriatric Medicine Society, American Geriatrics Society and ASBMR.

Conflict of interest

Adachi J.D. is consultant/speaker for Amgen, Eli Lilly, GSK, Merck, Novartis, Pfizer, Procter & Gamble, Roche, Sanofi Aventis and Warner Chilcott and received grants for clinical trials from Amgen, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Procter & Gamble, Sanofi Aventis, Roche and Warner Chilcott.

Agnusdei D. is a stock holder and employee of Eli Lilly and Company.

Bilezikian J.P. receives consultancies and speaker fees for Amgen, Lilly, Merck and Novartis; consultancies for Radius Pharmaceuticals, NPS Pharmaceuticals and GSK; and research support from NPS Pharmaceuticals.

Boonen S. receives research support and/or consulting fees from Amgen, Merck, Novartis, Sanofi Aventis and Warner Chilcott.

Cooper C. receives lecture fees and consultancy from ABBH, Amgen, Eli Lilly, GSK/Roche, MSD, Novartis, Nycomed and Servier.

Diez Perez A. receives honoraria as consultant or speaker from Amgen, Eli Lilly and MSD as well as research funds from Alliance of Bone Health and Servier.

Eastell R. is a member of the Procter & Gamble National Advisory Board, Medical Research Council, European Calcified Tissue Society, Biobank MSK Advisory Board; a consultant for Amgen, AstraZeneca, GlaxoSmithKline, Medtronics, Nastech, Nestle, Fonterra Brands, Novartis, Ono Pharma, Osteologix, Pfizer, Eli Lilly, Sanofi Aventis, Tethys, Unilever, Unipath, Inverness Medical, Johnson & Johnson, SPD and MSD and IDS; received grants from AstraZeneca, Unilever, Amgen, Department of Health, National Institute for Health Research, Sheffield Teaching Hospitals Trust, Queen Mary University of London, Procter & Gamble, Unipath Limited, Novartis, Medical Research Council UK, Arthritis Research UK, Nestle Foundation and Sanofi Aventis; received payment for lectures including service on speakers bureaus from Takeda, Eli Lilly, Amgen, National Osteoporosis Foundation, Procter & Gamble, GlaxoSmithKline Nutrition and Roche; received travel, accommodations or meeting expenses from Novartis, Procter & Gamble, GlaxoSmithKline Nutrition, Fonterra Brands, Amgen, AstraZeneca, Medtronics, Unilever, Ono Pharma, Servier, Tethys, Eli Lilly, SPD and International Osteoporosis Foundation.

Kanis J.A. receives consulting fees, paid advisory boards, lecture fees and/or grant support from the majority of companies concerned with skeletal metabolism.

Langdahl B. is a member of the advisory board of Amgen, Lilly, Nycomed and MSD and the speakers bureau of Lilly, Amgen and MSD; and received research funding from Lilly, Novartis, MSD and Amgen.

McCloskey E. receives research funding and/or advisory board and/or speaker's fees from the following: Amgen, AstraZeneca, GSK, Hologic, Innovus, Lilly, MSD, Novartis, Pfizer, Roche, Servier, Tethys and Warner Chilcott.

Napoli N. receives consultancy and lecture fees from MSD.

Ralston S. received research grants from Amgen and his employer received consultancy income from Amgen, Merck and Novartis.

Silverman S. is a member of the speaker's bureau for Amgen, Lilly, Pfizer and Roche Pharmaceuticals; a consultant for Amgen, Lilly, Novartis, Pfizer, Roche Pharmaceuticals, Roche Diagnostics and Warner Chilcott; and received research support from Alliance for Better Bone Health, Lilly and Pfizer.

Compston J.E. receives consultancy fees and lecture fees, and/or received grant support from the Alliance for Better Bone Health, Amgen, Eli Lilly, GlaxoSmithKline, Medtronic, MSD, Novartis, Nycomed, Procter & Gamble, Sanofi Aventis, Servier and Warner Chilcott.

Borgstrom F., Hofbauer L., Lekamwasam S., Lesnyak O., Lorenc R., Messina O.D., Obermayer-Pietsch B., Stepan J., Sambrook P., Sosa M., Suppan G. and Wahl D.A. declare no conflict of interest.

References

  1. 1.
    Compston JE (2010) Management of glucocorticoid-induced osteoporosis. Nature Rev Rheumatol 6:82–88CrossRefGoogle Scholar
  2. 2.
    American College of Rheumatology ad hoc Committee on Glucocorticoid-induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 44:1496–1503CrossRefGoogle Scholar
  3. 3.
    Royal College of Physicians (2002) Glucocorticoid-induced osteoporosis. Guidelines on prevention and treatment. Bone and Tooth Society of Great Britain, National Osteoporosis Society and Royal College of Physicians. Royal College of Physicians, LondonGoogle Scholar
  4. 4.
    Brown JP, Josse RG, Scientific Advisory Council of the Osteoporosis Society of Canada (2002) Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167:S1–S34PubMedGoogle Scholar
  5. 5.
    Devogelaer JP, Goemaere S, Boonen S, Body JJ, Kaufman JM, Reginster JY, Rozenberg S, Boutsen Y (2006) Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 17:8–19CrossRefPubMedGoogle Scholar
  6. 6.
    Geusens PP, Lems WF, Verhaar HJ, Leusink G, Goemaere S, Zmierczack H, Compston JE (2006) Review and evaluation of the Dutch guidelines for osteoporosis. J Eval Clin Pract 12:539–548CrossRefPubMedGoogle Scholar
  7. 7.
    Gourlay M, Franceschini N, Sheyn Y (2007) Prevention and treatment strategies for glucocorticoid-induced osteoporosis. Clin Rheumatol 26:144–153CrossRefPubMedGoogle Scholar
  8. 8.
    Hoes JN, Jacobs JW, Boers M, Boumpas D, Buttgereit F, Caeyers N, Choy EH, Cutolo M, Da Silva JA, Esselens G, Guillevin L, Hafstrom I, Kirwan JR, Rovensky J, Russell A, Saag KG, Svensson B, Westhovens R, Zeidler H, Bijlsma JW (2007) EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 66:1560–1567CrossRefPubMedGoogle Scholar
  9. 9.
    Nawata H, Soen S, Takayanagi R, Tanaka I, Takaoka K, Fukunaga M, Matsumoto T, Suzuki Y, Tanaka H, Fujiwara S, Miki T, Sagawa A, Nishizawa Y, Seino Y, Subcommittee to Study Diagnostic Criteria for Glucocorticoid-Induced Osteoporosis (2005) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab 23:105–109CrossRefPubMedGoogle Scholar
  10. 10.
    National Osteoporosis Foundation (2008) Clinician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington, DC, www.nof.org. Accessed 15 August 2011Google Scholar
  11. 11.
    Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, Curtis JR, Furst DE, McMahon M, Patkar NM, Volkmann E, Saag KG (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arth Care Res 62:1515–1526CrossRefGoogle Scholar
  12. 12.
    Díez-Pérez A, Hooven FH, Adachi JD, Adami S, Anderson FA, Boonen S, Chapurlat R, Compston JE, Cooper C, Delmas P, Greenspan SL, LaCroix AZ, Lindsay R, Netelenbos JC, Pfeilschifter J, Roux C, Saag KG, Sambrook P, Silverman S, Siris ES, Watts NB, Nika G, Gehlbach SH (2011) Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone 49:493–498CrossRefPubMedGoogle Scholar
  13. 13.
    van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787CrossRefPubMedGoogle Scholar
  14. 14.
    van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatol Phys Med 39:1383–1389CrossRefGoogle Scholar
  15. 15.
    van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:933–1000Google Scholar
  16. 16.
    Hoes JN, Jacobs JW, Hulsmans HM, De Nijs RN, Lems WF, Bruyn GA, Geusens PP, Bijlsma JW (2010) High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use. Extension of the alendronate or alfacalcidol in glucocorticoid-induced osteoporosis-trial. Clin Exp Rheumatol 28:354–359PubMedGoogle Scholar
  17. 17.
    Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton LJ III, Tenenhouse A, Reeve J, Silman AJ, Pols HA, Eisman JA, McCloskey EV, Mellstrom D (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19:893–899CrossRefPubMedGoogle Scholar
  18. 18.
    van Staa TP, Leufkens HG, Cooper C (2001) Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 16:581–588CrossRefPubMedGoogle Scholar
  19. 19.
    de Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, van Staa TP (2007) Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 56:208–214CrossRefPubMedGoogle Scholar
  20. 20.
    Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319–1328CrossRefPubMedGoogle Scholar
  21. 21.
    Hofbauer LC, Rauner M (2009) Minireview: live and let die: molecular effects of glucocorticoids on bone cells. Mol Endocrinol 23:1525–1531CrossRefPubMedGoogle Scholar
  22. 22.
    van de Berg BC, Malghem J, Lecouvet FE, Devogelaer JP, Maldague B, Houssiau FA (1999) Fat conversion of femoral marrow in glucocorticoid-treated patients: a cross-sectional and longitudinal study with magnetic resonance imaging. Arthritis Rheum 42:1405–1411CrossRefGoogle Scholar
  23. 23.
    Mak W, Shao X, Dunstan CR, Seibel MJ, Zhou H (2009) Biphasic glucocorticoid-dependent regulation of Wnt expression and its inhibitors in mature osteoblastic cells. Calcif Tissue Int 85:538–545CrossRefPubMedGoogle Scholar
  24. 24.
    Ohnaka K, Taniguchi H, Kawate H, Nawata H, Takayanagi R (2004) Glucocorticoid enhances the expression of dickkopf-1 in human osteoblasts: novel mechanism of glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun 21:259–264CrossRefGoogle Scholar
  25. 25.
    Wang FS, Ko JY, Yeh DW, Ke HC, Wu HL (2008) Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology 149:1793–1801CrossRefPubMedGoogle Scholar
  26. 26.
    Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC (1998) Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102:274–282CrossRefPubMedGoogle Scholar
  27. 27.
    Cherian PP, Xia X, Jiang JX (2008) Role of gap junction, hemichannels, and connexin 43 in mineralizing in response to intermittent and continuous application ofparathyroid hormone. Cell Commun Adhes 15:43–54CrossRefPubMedGoogle Scholar
  28. 28.
    Plotkin LI, Lezcano V, Thostenson J, Weinstein RS, Manolagas SC, Bellido T (2008) Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res 23:1712–1721CrossRefPubMedGoogle Scholar
  29. 29.
    Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S (1999) Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140:4382–4389CrossRefPubMedGoogle Scholar
  30. 30.
    Swanson C, Lorentzon M, Conaway HH, Lerner UH (2006) Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones. Endocrinology 147:3613–3622CrossRefPubMedGoogle Scholar
  31. 31.
    Kim HJ, Zhao H, Kitaura H, Bhattacharyya S, Brewer JA, Muglia LJ, Ross FP, Teitelbaum SL (2006) Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 116:2152–2160CrossRefPubMedGoogle Scholar
  32. 32.
    Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12CrossRefPubMedGoogle Scholar
  33. 33.
    World Health Organization (2007) Assessment of osteoporosis at the primary health care level. At: http://www.who.int/chp/topics/Osteoporosis.pdf. Accessed 15 August 2011
  34. 34.
    Kanis JA on behalf of the World Health Organization Scientific Group (2008) Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK. Available at: http://wwwshefacuk/FRAX/indexhtm. Accessed 15 August 2011
  35. 35.
    Kanis JA, Johnell O, Oden A, Johansson H, McCloskey EV (2008) FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397CrossRefPubMedGoogle Scholar
  36. 36.
    Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown JP, Burckhardt P, Cooper C, Christiansen C, Cummings S, Eisman JA, Fujiwara S, Glüer C, Goltzman D, Hans D, Krieg MA, La Croix A, McCloskey E, Mellstrom D, Melton LJ 3rd, Pols H, Reeve J, Sanders K, Schott AM, Silman A, Torgerson D, van Staa T, Watts NB, Yoshimura N (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033–1046CrossRefPubMedGoogle Scholar
  37. 37.
    Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Oglesby A (2002) International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res 17:1237–1244CrossRefPubMedGoogle Scholar
  38. 38.
    Association Suisse contre l‘Ostéoporose (2010) Ostéoporose: Recommandations 2010. ASCO http://wwwsvgoch/content/documents/SVGO_Empfehlungen2010_V19April2010pdf. Accessed 15 August 2011
  39. 39.
    Socialstyrelsen (2010) Nationella riktlinjer för rörelseorganens sjukdomar 2010 - stöd för styrning och ledning. Preliminär version. Artikelnr 2010-11-15. Published at www.socialstyrelsen.se. Accessed 15 August 2011.
  40. 40.
    Compston JE, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, McCloskey EV, Reid DM, Selby P, Wilkins M, National Osteoporosis Guideline Group (NOGG) (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62:105–108CrossRefPubMedGoogle Scholar
  41. 41.
    Czerwinski E, Kanis JA, Trybulec B, Johansson H, Borowy P, Osieleniec J (2009) The incidence and risk of hip fracture in Poland. Osteoporos Int 20:1363–1368CrossRefPubMedGoogle Scholar
  42. 42.
    Dawson-Hughes B (2008) A revised clinician's guide to the prevention and treatment of osteoporosis. J Clin Endocrinol Metab 93:2463–2465CrossRefPubMedGoogle Scholar
  43. 43.
    Fujiwara S, Nakamura T, Orimo H, Hosoi T, Gorai I, Oden A, Johansson H, Kanis JA (2008) Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX™). Osteoporos Int 19:429–448CrossRefPubMedGoogle Scholar
  44. 44.
    Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R, European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428CrossRefPubMedGoogle Scholar
  45. 45.
    Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A, National Osteoporosis Guideline Group (2008) Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK. Osteoporos Int 19:1395–1408, Erratum 2009 Osteoporos Int 20: 499-502CrossRefPubMedGoogle Scholar
  46. 46.
    Lippuner K, Johansson H, Kanis JA, Rizzoli R (2010) FRAX® assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int 21:381–390CrossRefPubMedGoogle Scholar
  47. 47.
    Neuprez A, Johansson H, Kanis JA, McCloskey EV, Odén A, Bruyère O, Hiligsmann M, Devogelaer JP, Kaufman JM, Reginster JY (2009) Rationalisation du remboursement des médicaments de l’ostéoporose: de la mesure isolée de la densité osseuse à l’intégration des facteurs cliniques de risque fracturaire. Validation de l’algorithme FRAX®. La Revue Médicale de Liège 64:612–619Google Scholar
  48. 48.
    Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM, Kvern B, Siminoski K, Leslie WD, Scientific Advisory Council of Osteoporosis Canada (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182:1864–1873CrossRefPubMedGoogle Scholar
  49. 49.
    Kanis JA, Johnell O, Committee of Scientific Advisors of the International Osteoporosis Foundation (2005) Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 16:229–238CrossRefPubMedGoogle Scholar
  50. 50.
    Kanis JA, McCloskey E, Johansson H, Oden A, Leslie WD (2012) FRAX® with and without bone mineral density. Calcif Tissue Int 90:1–13CrossRefPubMedGoogle Scholar
  51. 51.
    Leib ES, Saag KG, Adachi JD, Geusens PP, Binkley N, McCloskey EV, Hans DB, FRAX(®) Position Development Conference Members (2011) The impact of the use of glucocorticoids on the estimate by FRAX of the 10 year risk of fracture. J Clin Densitom 14:212–219CrossRefPubMedGoogle Scholar
  52. 52.
    van Staa TP, Abenhaim L, Cooper C, Zhang B, Leufkens HG (2001) Public health impact of adverse bone effects of oral corticosteroids. Br J Clin Pharmacol 51:601–607CrossRefPubMedGoogle Scholar
  53. 53.
    van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Fracture and oral corticosteroids: relationship to daily and cumulative dose. Rheumatol 39:1383–1389CrossRefGoogle Scholar
  54. 54.
    Kanis JA, Johansson H, Oden A, McCloskey E (2011) Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 22:809–816CrossRefPubMedGoogle Scholar
  55. 55.
    Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Dawson-Hughes B, El-Hajj Fuleihan G, Johansson H, Leslie WD, Lewiecki EM, Luckey M, Oden A, Papapoulos SE, Poiana C, Rizzoli R, Wahl DA, McCloskey EV, Task Force of the Frax Initiative (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22:2395–2411CrossRefPubMedGoogle Scholar
  56. 56.
    Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA (2011) Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporos Int 22:839–847CrossRefPubMedGoogle Scholar
  57. 57.
    Nawata H, Soen S, Takayanagi R, Tanaka I, Takaoka K, Fukunaga M, Matsumoto T, Suzuki Y, Tanaka H, Fujiwara S, Miki T, Sagawa A, Nishizawa Y, Seino Y (2005) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab 23:105–109CrossRefPubMedGoogle Scholar
  58. 58.
    Agence Française de Sécurité Sanitaire des Produits de Santé (2006) Traitement medicamenteux de l’osteoporose post-ménopausique – Recommandations http://www.afssaps.fr/content/download/7843/78935/version/7/file/ostemrec.pdf (Updated 2008 http://sante-medecine.commentcamarche.net/faq/1118-les-traitementsde-l-osteoporose-post-menopausique-afssaps). Accessed 08 November 2011.
  59. 59.
    Adami S, Bertoldo F, Brandi M-L, Cepollaro C, Filipponi P, Fiore E, Frediani B, Giannini S, Gonnelli S, Isaia GC, Luisetto G, Mannarino E, Marcocci C, Masi L, Mereu C, Migliaccio S, Minisola S, Nuti R, Rini G, Rossini M, Varenna M, Ventura L, Bianchi G, Società Italiana dell'Osteoporosi, del Metabolismo Minerale e delle Malattie dello Scheletro (2009) Guidelines for the diagnosis, prevention and treatment of osteoporosis. Reumatismo 61:260–284PubMedGoogle Scholar
  60. 60.
    González Macias J, Guañabens N, Gomez Alonso C, del Rio Barquero L, Munoz Torres M, Delgado M, Perez Edo L, Bernardino Diaz Lopez J, Jodar Gimeno E, Hawkins Carranza F, Comité de Redacción, en representación del Comité de Expertos de la SEIOMM para la elaboración de las Guías (2008) Practice guidelines for postmenopausal, steroid-induced and male osteoporosis. Spanish Society for Bone and Mineral Research. Rev Clin Esp 208(Suppl1):1–24CrossRefGoogle Scholar
  61. 61.
    Dawson-Hughes B, Tosteson AN, Melton LJ, Baim S, Favus MJ, Khosla S, Lindsay RL, National Osteoporosis Foundation Guide Committee (2008) Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 19:449–458CrossRefPubMedGoogle Scholar
  62. 62.
    Kanis JA, Borgstrom F, Zethraeus N, Johnell O, Oden A, Jonsson B (2005) Intervention thresholds for osteoporosis in the UK. Bone 36:22–32CrossRefPubMedGoogle Scholar
  63. 63.
    European Community (1998) Report on osteoporosis in the European Community. 1998. EC, StrasbourgGoogle Scholar
  64. 64.
    Royal College of Physicians (1999) Osteoporosis: clinical guidelines for the prevention and treatment. Royal College of Physicians, LondonGoogle Scholar
  65. 65.
    Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D, European Foundation for Osteoporosis and Bone Disease (1997) Guidelines for diagnosis and management of osteoporosis. Osteoporos Int 7:390–406CrossRefPubMedGoogle Scholar
  66. 66.
    Strom O, Borgstrom F, Kanis JA, Compston JE, Cooper C, McCloskey E, Jonsson B (2011) Osteoporosis; burden, health care provision and opportunities in the EU. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 6:59–155CrossRefPubMedGoogle Scholar
  67. 67.
    Johansson H, Kanis JA, Oden A, Johnell O, Compston J, McCloskey EV (2011) A comparison of case finding strategies in the UK for the management of hip fractures. Osteoporos Int 23:907–915CrossRefGoogle Scholar
  68. 68.
    Leslie WD, Morin S, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA, Manitoba Bone Density Program (2012) Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporos Int 23:75–85CrossRefPubMedGoogle Scholar
  69. 69.
    Johansson H, Kanis JA, Oden A, Johnell O, McCloskey E (2009) BMD, clinical risk factors and their combination for hip fracture prevention. Osteoporos Int 20:1675–1682CrossRefPubMedGoogle Scholar
  70. 70.
    Johansson H, Oden A, Johnell O, Jonsson B, De Laet C, Oglesby A, McCloskey EV, Kayan K, Jalava T, Kanis JA (2004) Optimisation of BMD measurements to identify high risk groups for treatment—a test analysis. J Bone Miner Res 19:906–913CrossRefPubMedGoogle Scholar
  71. 71.
    Kanis JA, Adams J, Borgström F, Cooper C, Jönsson B, Preedy D, Selby P, Compston J (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42:4–15CrossRefPubMedGoogle Scholar
  72. 72.
    Leslie WD, Lix LM, Majumdar SR, Johansson H, Oden A, McCloskey E, Kanis JA, Manitoba Bone Density Program (2011) High fracture probability with FRAX® usually indicates densitometric osteoporosis: implications for clinical practice. Osteoporos Int. doi: 10.1007/s00198-00011-01592-00193
  73. 73.
    Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M (2007) Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 11:1–256Google Scholar
  74. 74.
    Tosteson AN, Melton LJr, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL, National Osteoporosis Foundation Guide Committee (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437–447CrossRefPubMedGoogle Scholar
  75. 75.
    Middleton ET, Gardiner ED, Steel SA (2009) Which women should be selected for vertebral fracture assessment? Comparing different methods of targeting VFA. Calcif Tissue Int 85:203–210CrossRefPubMedGoogle Scholar
  76. 76.
    Compston J, Reid DM, Boisdron J, Brandi ML, Burlet N, Cahall D, Delmas PD, Dere W, Devogelaer JP, Fitzpatrick LA, Flamion B, Goel N, Korte S, Laslop A, Mitlak B, Ormarsdottir S, Ringe J, Rizzoli R, Tsouderos Y, van Staa T, Reginster JY, Group for the Respect of Ethics and Excellence in Science (2008) Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science. Osteoporos Int 19:1247–1250CrossRefPubMedGoogle Scholar
  77. 77.
    Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MO, Siminoski KG, Nevitt MC, Sharp JT, Malice MP, Dumortier T, Czachur M, Carofano W, Daifotis AG (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202–211CrossRefPubMedGoogle Scholar
  78. 78.
    de Nijs RN, Jacobs JW, Lems WF, Laan RF, Algra A, Huisman AM, Buskens E, de Laet CE, Oostveen AC, Geusens PP, Bruyn GA, Dijkmans BA, Bijlsma JW, Investigators STOP (2006) Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 355:675–684CrossRefPubMedGoogle Scholar
  79. 79.
    Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339:292–299CrossRefPubMedGoogle Scholar
  80. 80.
    Stoch SA, Saag KG, Greenwald M, Sebba AI, Cohen S, Verbruggen N, Giezek H, West J, Schnitzer TJ (2009) Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol 36:1705–1714CrossRefPubMedGoogle Scholar
  81. 81.
    Yilmaz L, Ozpran K, Gündüz OH, Ucan H, Yücel M (2001) Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids. Rheumatol Int 20:65–69CrossRefPubMedGoogle Scholar
  82. 82.
    Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA (1997) Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337:382–387CrossRefPubMedGoogle Scholar
  83. 83.
    Cortet B, Hachulla E, Barton I, Bonvoisin B, Roux C (1999) Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. Rev Rheumatol 66:214–219Google Scholar
  84. 84.
    Geusens P, Dequecker J, Vanhoof J, Stalmans R, Boonen S, Joly J, Nijs J, Raus J (1998) Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study. Ann Rheum Dis 57:724–727CrossRefPubMedGoogle Scholar
  85. 85.
    Jenkins EA, Walker-Bone KE, Wood A, McCrae FC, Cooper C, Cawley MI (1999) The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate. Scand J Rheumatol 28:152–156CrossRefPubMedGoogle Scholar
  86. 86.
    Jinnouchi Y (2000) Efficacy of intermittent etidronate therapy for corticosteroid-induced osteoporosis in patients with diffuse connective tissue disease. Kurume Med J 47:219–224CrossRefPubMedGoogle Scholar
  87. 87.
    Mulder H, Struys A (1994) Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 33:348–350CrossRefPubMedGoogle Scholar
  88. 88.
    Pitt P, Li F, Todd P, Webber D, Pack S, Moniz C (1998) A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long term oral corticosteroid treatment. Thorax 53:351–356CrossRefPubMedGoogle Scholar
  89. 89.
    Roux C, Oriente P, Laan R, Hughes RA, Ittner J, Goemaere S, Di Munno O, Pouillès JM, Horlait S, Cortet B (1998) Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. J Clin Endocrinol Metab 83:1128–1133CrossRefPubMedGoogle Scholar
  90. 90.
    Skingle SJ, Crisp AJ (1994) Increased bone density in patients on steroids with etidronate. Lancet Infect Dis 344:543–544Google Scholar
  91. 91.
    Struys A, Snelder AA, Mulder H (1995) Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 99:235–242CrossRefPubMedGoogle Scholar
  92. 92.
    Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA (1999) Risedronate therapy prevents corticosteroid-induced bone loss: a twelve month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42:2309–2318CrossRefPubMedGoogle Scholar
  93. 93.
    Eastell R, Devogelaer J-P, Peel NFA, Chines AA, Bax DE, Sacco-Gibson N, Nagant de Deuxchaisnes C, Russell RG (2000) Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 11:331–337CrossRefPubMedGoogle Scholar
  94. 94.
    Reid DM, Adami S, Devogelaer JP, Chines AA (2001) Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 69:242–247CrossRefPubMedGoogle Scholar
  95. 95.
    Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 15:1006–1013CrossRefPubMedGoogle Scholar
  96. 96.
    Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, Barton I, Chines AA (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67:277–285CrossRefPubMedGoogle Scholar
  97. 97.
    Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN, HORIZON investigators (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373:1253–1263CrossRefPubMedGoogle Scholar
  98. 98.
    Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028–2039CrossRefPubMedGoogle Scholar
  99. 99.
    Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60:3346–3355CrossRefPubMedGoogle Scholar
  100. 100.
    Lakatos P, Nagy Z, Kiss L, Horvath CS, Takacs I, Foldes J, Speer G, Bossanyi A (2000) Prevention of corticosteroid-induced osteoporosis by alfacalcidol. Z Rheumatol 59(suppl 1):48–52CrossRefPubMedGoogle Scholar
  101. 101.
    Reginster JY, Kuntz D, Verdickt W, Wouters M, Guillevin L, Menkes CJ, Nielsen K (1999) Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int 9:75–81CrossRefPubMedGoogle Scholar
  102. 102.
    Ringe JD, Cöster A, Meng T, Schacht E, Umbach R (1999) Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium. Calcif Tissue Int 65:337–340CrossRefPubMedGoogle Scholar
  103. 103.
    Sambrook PN, Kotowicz M, Nash P, Styles CB, Naganathan V, Henderson-Briffa KN, Eisman JA, Nicholson GC (2003) Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 18:919–924CrossRefPubMedGoogle Scholar
  104. 104.
    Yamada H (1989) Long-term effect of 1a-hydroxyvitamin D, calcium and thiazide administration on glucocorticoid-induced osteoporosis. Folia Endocrinol Jap 65:603–614Google Scholar
  105. 105.
    Diamond T, McGuigan I, Schonell M, Levy S, Rae D (1997) A 2 year open randomised controlled trial comparing calcitriol to cyclical etidronate for the treatment of glucocorticoid-induced osteoporosis. J Bone Miner Res 12:S311CrossRefGoogle Scholar
  106. 106.
    Dykman TR, Haralson KM, Gluck OS, Murphy WA, Teitelbaum SL, Hahn TJ, Hahn BH (1984) Effect of oral 1,25-dhydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 27:1336–1343CrossRefPubMedGoogle Scholar
  107. 107.
    Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ (2000) Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85:2129–2134CrossRefPubMedGoogle Scholar
  108. 108.
    Morris HA, Need AG, O'Loughlin PD, Horowitz M, Bridges A, Nordin BE (1990) Malabsorption of calcium in corticosteroid-induced osteoporosis. Calcif Tissue Int 46:305–308CrossRefPubMedGoogle Scholar
  109. 109.
    Boutsen Y, Jamart J, Esselinckx W, Devogelaer J-P (2001) Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res 16:104–112CrossRefPubMedGoogle Scholar
  110. 110.
    Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, Eisman J (1993) Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 328:1747–1752CrossRefPubMedGoogle Scholar
  111. 111.
    Sambrook PN (2000) Corticosteroid osteoporosis: practical implications of recent trials. J Bone Miner Res 15:1645–1649CrossRefPubMedGoogle Scholar
  112. 112.
    Holick MF (2007) Optimal vitamin d status for the prevention and treatment of osteoporosis. Drugs Aging 24:1017–1029CrossRefPubMedGoogle Scholar
  113. 113.
    Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM (1996) Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 125:961–968PubMedGoogle Scholar
  114. 114.
    Amin S, LaValley MP, Simms RW, Felson DT (1999) The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Arthritis Rheum 42:1740–1751CrossRefPubMedGoogle Scholar
  115. 115.
    Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P (2000) Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2:CD000952.Google Scholar
  116. 116.
    Richy F, Schacht E, Bruyere O, Ethgen O, Gourlay M, Reginster JY (2005) Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis. Calcif Tissue Int 76:176–186CrossRefPubMedGoogle Scholar
  117. 117.
    Abrahamsen B, Sahota O (2011) Do calcium plus vitamin D supplements increase cardiovascular risk? BMJ 342:d2080CrossRefPubMedGoogle Scholar
  118. 118.
    Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA (2011) The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 96:53–58CrossRefPubMedGoogle Scholar
  119. 119.
    Fleurence RL, Iglesias CP, Johnson JM (2007) The cost-effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literautre. Pharmacoeconomics 25:913–933CrossRefPubMedGoogle Scholar
  120. 120.
    Zethraeus N, Borgstrom F, Strom O, Kanis JA, Jonsson B (2007) Cost-effectiveness of the treatment and prevention of osteoporosis–a review of the literature and a reference model. Osteoporos Int 18:9–23CrossRefPubMedGoogle Scholar
  121. 121.
    Beukelman T, Saag KG, Curtis JR, Kilgore ML, Pisu M (2010) Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis. Osteoporos Int 21:1573–1584CrossRefPubMedGoogle Scholar
  122. 122.
    Buckley LM, Hillner BE (2003) A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids. J Rheumatol 30:132–138PubMedGoogle Scholar
  123. 123.
    Solomon DH, Kuntz KM (2000) Should postmenopausal women with rheumatoid arthritis who are starting corticosteroid treatment be screened for osteoporosis? A cost-effectiveness analysis. Arthritis Rheum 43:1967–1975CrossRefPubMedGoogle Scholar
  124. 124.
    van Staa TP, Geusens P, Zhang B, Leufkens HG, Boonen S, Cooper C (2007) Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids. Rheumatol 46:460–466CrossRefGoogle Scholar
  125. 125.
    Ström O, Borgström F, Sen SS, Boonen S, Haentjens P, Johnell O, Kanis JA (2007) Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries—an economic evaluation based on the fracture intervention trial. Osteoporos Int 18:1047–1061CrossRefPubMedGoogle Scholar
  126. 126.
    Borgstrom F, Strom O, Coelho J, Johansson H, Oden A, McCloskey EV, Kanis JA (2010) The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int 21:495–505CrossRefPubMedGoogle Scholar
  127. 127.
    Rizzoli R, Akesson K, Bouxsein M, Kanis JA, Napoli N, Papapoulos S, Reginster JY, Cooper C (2011) Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 22:373–390CrossRefPubMedGoogle Scholar
  128. 128.
    Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M, American Society for Bone and Mineral Research (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267–2294CrossRefPubMedGoogle Scholar
  129. 129.
    Giusti A, Hamdy NA, Dekkers OM, Ramautar SR, Dijkstra S, Papapoulos SE (2011) Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone 48:966–971CrossRefPubMedGoogle Scholar
  130. 130.
    Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, Whelan DB, Weiler PJ, Laupacis A (2010) Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 305:783–789CrossRefGoogle Scholar
  131. 131.
    Schilcher J, Michaëlsson K, Aspenberg P (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364:1728–1737CrossRefPubMedGoogle Scholar
  132. 132.
    Wang Z, Bhattacharyya T (2011) Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007. J Bone Miner Res 26:553–560CrossRefPubMedGoogle Scholar
  133. 133.
    Armamento-Villareal R, Napoli N, Diemer K, Watkins M, Civitelli R, Teitelbaum S, Novack D (2009) Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int 85:37–44CrossRefPubMedGoogle Scholar
  134. 134.
    Edwards MH, McCrae FC, Young-Min SA (2010) Alendronate-related femoral diaphysis fracture-what should be done to predict and prevent subsequent fracture of the contralateral side? Osteoporos Int 21:701–703CrossRefPubMedGoogle Scholar
  135. 135.
    Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS (2007) Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 89:349–353CrossRefPubMedGoogle Scholar
  136. 136.
    Ing-Lorenzini K, Desmeules J, Plachta O, Suva D, Dayer P, Peter R (2009) Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf 32:775–785CrossRefPubMedGoogle Scholar
  137. 137.
    Kwek EB, Goh SK, Koh JS, Png MA, Howe TS (2008) An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39:224–231CrossRefPubMedGoogle Scholar
  138. 138.
    Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294–1301CrossRefPubMedGoogle Scholar
  139. 139.
    Visekruna M, Wilson D, McKiernan FE (2008) Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 93:2948–2952CrossRefPubMedGoogle Scholar
  140. 140.
    Khan AA, Sándor GK, Dore E, Morrison AD, Alsahli M, Amin F, Peters E, Hanley DA, Chaudry SR, Lentle B, Dempster DW, Glorieux FH, Neville AJ, Talwar RM, Clokie CM, Mardini MA, Paul T, Khosla S, Josse RG, Sutherland S, Lam DK, Carmichael RP, Blanas N, Kendler D, Petak S, Ste-Marie LG, Brown J, Evans AW, Rios L, Compston JE, Canadian Taskforce on Osteonecrosis of the Jaw (2009) Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 36:478–490CrossRefPubMedGoogle Scholar
  141. 141.
    Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo S-B, Shane E (2007) Bisphosphonate–associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479–1491CrossRefPubMedGoogle Scholar
  142. 142.
    Durie BG, Katz M, Crowley J (2005) Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353:99–102CrossRefPubMedGoogle Scholar
  143. 143.
    Lazarovici TS, Yahalom R, Taicher S, Elad S, Hardan I, Yarom N (2009) Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients. J Oral Maxillofac Surg 67:850–855CrossRefPubMedGoogle Scholar
  144. 144.
    Woo SB, Hellstein JW, Kalmar JR (2006) Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753–761PubMedGoogle Scholar
  145. 145.
    Patlas N, Golomb G, Yaffe P, Pinto T, Breuer E, Ornoy A (1999) Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 60:68–73CrossRefPubMedGoogle Scholar
  146. 146.
    Losada I, Sartori L, Di Gianantonio E, Zen M, Clementi M, Doria A (2010) Bisphosphonates in patients with autoimmune rheumatic diseases: can they be used in women of childbearing age? Autoimmun Rev 9:547–552CrossRefPubMedGoogle Scholar
  147. 147.
    Levy S, Fayez I, Taguchi N, Han JY, Aiello J, Matsui D, Moretti M, Koren G, Ito S (2009) Pregnancy outcome following in utero exposure to bisphosphonates. Bone 44:428–430CrossRefPubMedGoogle Scholar
  148. 148.
    Ornoy A, Wajnberg R, Diav-Citrin O (2006) The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment. Reprod Toxicol 22:578–579CrossRefPubMedGoogle Scholar
  149. 149.
    Baim S, Wilson CR, Lewiecki EM, Luckey MM, Downs RJ, Lentle BC (2005) Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry. J Clin Densitom 8:371–378CrossRefPubMedGoogle Scholar
  150. 150.
    Frost SA, Nguyen ND, Center JR, Eisman JA, Nguyen TV (2009) Timing of repeat BMD measurements: development of an absolute risk-based prognostic model. J Bone Miner Res 24:1800–1807CrossRefPubMedGoogle Scholar
  151. 151.
    Gluer CC, Blake G, Lu Y, Blunt BA, Jergas M, Genant HK (1995) Accurate assessment of precision errors: how to measure the reproducibility of bone densitometry techniques. Osteoporos Int 19:1395–1408, Erratum 2009 Osteoporos Int 20: 499-502 5:262-270Google Scholar
  152. 152.
    Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM (2002) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281–289CrossRefPubMedGoogle Scholar
  153. 153.
    Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW, Johnston CC, Kleerekoper M, Lindsay R, Luckey MM, McClung MR, Nankin HR, Petak SM, Recker RR, AACE Osteoporosis Task Force (2003) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 9:544–564PubMedGoogle Scholar
  154. 154.
    Lenchik L, Kiebzak GM, Blunt BA (2002) What is the role of serial bone mineral density measurements in patient management? J Clin Densitom 5:S29–38CrossRefPubMedGoogle Scholar
  155. 155.
    Watts NB, Lewiecki EM, Bonnick SL, Laster AJ, Binkley N, Blank RD, Geusens PP, Miller PD, Petak SM, Recker RR, Saag KG, Schousboe J, Siris ES, Bilezikian JP (2009) Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res 24:1643–1646CrossRefPubMedGoogle Scholar
  156. 156.
    Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, Griesmacher A, McClung M, Morris HA, Silverman S, Trenti T, Wahl DA, Cooper C, Kanis JA, IOF-IFCC Bone Marker Standards Working Group (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22:391–420CrossRefPubMedGoogle Scholar
  157. 157.
    Eastell R, Krege JH, Chen P, Glass EV, Reginster JY (2006) Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 22:61–66CrossRefPubMedGoogle Scholar
  158. 158.
    Kumagai S, Kawano S, Atsumi T, Inokuma S, Okada Y, Kanai Y, Kaburaki J, Kameda H, Suwa A, Hagiyama H, Hirohata S, Makino H, Hashimoto H (2005) Vertebral fracture and bone mineral density in women receiving high dose glucocorticoids for treatment of autoimmune diseases. J Rheumatol 32:863–869PubMedGoogle Scholar
  159. 159.
    Kaji H, Yamauchi M, Chihara K, Sugimoto T (2008) Glucocorticoid excess affects cortical bone geometry in premenopausal, but not postmenopausal, women. Calcif Tissue Int 82:182–190CrossRefPubMedGoogle Scholar
  160. 160.
    Kaji H, Yamauchi M, Yamaguchi T, Sugimoto T (2010) Urinary deoxypyridinoline is a BMD-independent marker for prevalent vertebral fractures in postmenopausal women treated with glucocorticoid. Osteoporos Int 21:1585–1590CrossRefPubMedGoogle Scholar
  161. 161.
    Honkanen R, Tuppurainen M, Kroger H, Alhava E, Puntila E (1997) Associations of early premenopausal fractures with subsequent fractures vary by sites and mechanisms of fractures. Calcif Tissue Int 60:327–331CrossRefPubMedGoogle Scholar
  162. 162.
    Hosmer WD, Genant HK, Browner WS (2002) Fractures before menopause: a red flag for physicians. Osteoporos Int 13:337–341CrossRefPubMedGoogle Scholar
  163. 163.
    Horowitz M, Wishart JM, Bochner M, Need AG, Chatterton BE, Nordin BE (1988) Mineral density of bone in the forearm in premenopausal women with fractured wrists. BMJ 297:1314–1315CrossRefPubMedGoogle Scholar
  164. 164.
    Armamento-Villareal R, Villareal DT, Avioli LV, Civitelli R (1992) Estrogen status and heredity are major determinants of premenopausal bone mass. J Clin Invest 90:2464–2471CrossRefPubMedGoogle Scholar
  165. 165.
    Cohen A, Fleischer J, Freeby MJ, McMahon DJ, Irani D, Shane E (2009) Clinical characteristics and medication use among premenopausal women with osteoporosis and low BMD: the experience of an osteoporosis referral center. J Womens Health 18:79–84CrossRefGoogle Scholar
  166. 166.
    Moreira Kulak CA, Schussheim DH, McMahon DJ, Kurland E, Silverberg SJ, Siris ES, Bilezikian JP, Shane E (2000) Osteoporosis and low bone mass in premenopausal and perimenopausal women. Endocr Pract 6:296–304PubMedGoogle Scholar
  167. 167.
    Peris P, Guañabens N, Martínez J, de Osaba M, Monegal A, Alvarez L, Pons F, Ros I, Cerdá D, Muñoz-Gómez J (2002) Clinical characteristics and etiologic factors of premenopausal osteoporosis in a group of Spanish women. Semin Arthritis Rheum 32:64–70CrossRefPubMedGoogle Scholar
  168. 168.
    Blum M, Harris SS, Must A, Phillips SM, Rand WM, Dawson-Hughes B (2001) Weight and body mass index at menarche are associated with premenopausal bone mass. Osteoporos Int 12:588–594CrossRefPubMedGoogle Scholar
  169. 169.
    Hawker GA, Jamal SA, Ridout R, Chase C (2002) A clinical prediction rule to identify premenopausal women with low bone mass. Osteoporos Int 13:400–406CrossRefPubMedGoogle Scholar
  170. 170.
    Sugiyama T, Suzuki S, Yoshida T, Suyama K, Tanaka T, Sueishi M, Tatsuno I (2010) Incidence of symptomatic vertebral fractures in women of childbearing age newly treated with high-dose glucocorticoid. Gend Med 7:218–229CrossRefPubMedGoogle Scholar
  171. 171.
    Tatsuno I, Sugiyama T, Suzuki S, Yoshida T, Tanaka T, Sueishi M, Saito Y (2009) Age dependence of early symptomatic vertebral fracture with high-dose glucocorticoid treatment for collagen vascular diseases. J Clin Endocrinol Metab 94:1671–1677CrossRefPubMedGoogle Scholar
  172. 172.
    Yirmiya R, Bab I (2009) Major depression is a risk factor for low bone mineral density: a meta-analysis. Biol Psychiatry 66:423–432CrossRefPubMedGoogle Scholar
  173. 173.
    Solomon DH, Katz JN, Jacobs JP, La Tourette AM, Coblyn J (2002) Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice. Arthritis Rheum 46:3136–3142CrossRefPubMedGoogle Scholar
  174. 174.
    Roux C, Reid DM, Devogelaer JP, Saag K, Lau CS, Reginster JY, Papanastasiou P, Bucci-Rechtweg C, Su G, Sambrook PN (2011) Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Osteoporos Int. doi: 10.1007/s00198-00011-01800-00191
  175. 175.
    Langdahl BL, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M, Krohn K, See K, Warner MR (2009) Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int 20:2095–2104CrossRefPubMedGoogle Scholar
  176. 176.
    Yeap SS, Fauzi AR, Kong NC, Halim AG, Soehardy Z, Rahimah I, Chow SK, Goh EM (2008) A comparison of calcium, calcitriol, and alendronate in corticosteroid-treated premenopausal patients with systemic lupus erythematosus. J Rheumatol 35:2344–2347CrossRefPubMedGoogle Scholar
  177. 177.
    Okada Y, Nawata M, Nakayamada S, Saito K, Tanaka Y (2008) Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy. J Rheumatol 35:2249–2254CrossRefPubMedGoogle Scholar
  178. 178.
    Nakayamada S, Okada Y, Saito K, Tanaka Y (2004) Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases. J Rheumatol 31:163–166PubMedGoogle Scholar
  179. 179.
    Sato S, Ohosone Y, Suwa A, Yasuoka H, Nojima T, Fujii T, Kuwana M, Nakamura K, Mimori T, Hirakata M (2003) Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year follow-up. J Rheumatol 30:2673–2679PubMedGoogle Scholar
  180. 180.
    Sato S, Takada T, Katsuki Y, Kimura N, Kaneko Y, Suwa A, Hirakata M, Kuwana M (2008) Longterm effect of intermittent cyclical etidronate therapy on corticosteroid-induced osteoporosis in Japanese patients with connective tissue disease: 7-year followup. J Rheumatol 35:142–146PubMedGoogle Scholar
  181. 181.
    Mok CC, Tong KH, To CH, Siu YP, Ma KM (2008) Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial. Osteoporos Int 19:357–364CrossRefPubMedGoogle Scholar
  182. 182.
    Fujii N, Hamano T, Mikami S, Nagasawa Y, Isaka Y, Moriyama T, Horio M, Imai E, Hori M, Ito T (2007) Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD). Nephrol Dial Transplant 22:1601–1607CrossRefPubMedGoogle Scholar
  183. 183.
    Kikuchi Y, Imakiire T, Yamada M, Saigusa T, Hyodo T, Kushiyama T, Higashi K, Hyodo N, Yamamoto K, Suzuki S, Miura S (2007) Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease. Nephrol Dial Transplant 22:1593–1600CrossRefPubMedGoogle Scholar
  184. 184.
    Lambrinoudaki I, Chan DT, Lau CS, Wong RW, Yeung SS, Kung AW (2000) Effect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy. A randomized, double blind, placebo controlled study. J Rheumatol 27:1759–1765PubMedGoogle Scholar
  185. 185.
    Bernstein CN, Seeger LL, Anton PA, Artinian L, Geffrey S, Goodman W, Belin TR, Shanahan F (1996) A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther 10:777–786CrossRefPubMedGoogle Scholar
  186. 186.
    McDonald CF, Zebaze RM, Seeman E (2006) Calcitriol does not prevent bone loss in patients with asthma receiving corticosteroid therapy: a double-blind placebo-controlled trial. Osteoporos Int 17:1546–1551CrossRefPubMedGoogle Scholar
  187. 187.
    Kung AW, Chan TM, Lau CS, Wong RW, Yeung SS (1999) Osteopenia in young hypogonadal women with systemic lupus erythematosus receiving chronic steroid therapy: a randomized controlled trial comparing calcitriol and hormonal replacement therapy. Rheumatology (Oxford) 38:1239–1244CrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2012

Authors and Affiliations

  • S. Lekamwasam
    • 1
  • J. D. Adachi
    • 2
  • D. Agnusdei
    • 3
  • J. Bilezikian
    • 4
  • S. Boonen
    • 5
  • F. Borgström
    • 6
  • C. Cooper
    • 7
  • A. Diez Perez
    • 8
  • R. Eastell
    • 9
  • L. C. Hofbauer
    • 10
  • J. A. Kanis
    • 11
  • B. L. Langdahl
    • 12
  • O. Lesnyak
    • 13
  • R. Lorenc
    • 14
  • E. McCloskey
    • 9
  • O. D. Messina
    • 15
  • N. Napoli
    • 16
  • B. Obermayer-Pietsch
    • 17
  • S. H. Ralston
    • 18
  • P. N. Sambrook
    • 19
  • S. Silverman
    • 20
  • M. Sosa
    • 21
  • J. Stepan
    • 22
    • 23
  • G. Suppan
    • 24
  • D. A. Wahl
    • 26
  • J. E. Compston
    • 25
    Email author
  • Joint IOF-ECTS GIO Guidelines Working Group
  1. 1.Department of Medicine, Faculty of MedicineCentre for Metabolic Bone DiseasesGalleSri Lanka
  2. 2.Division of Rheumatology, Department of MedicineMcMaster UniversityHamiltonCanada
  3. 3.Eli Lilly and Co.FlorenceItaly
  4. 4.College of Physicians and SurgeonsColumbia UniversityNew YorkUSA
  5. 5.Division of Gerontology and Geriatrics and Center for Musculoskeletal Research, Department of Experimental MedicineLeuven UniversityLeuvenBelgium
  6. 6.Quantify Research and LIME/MMCKarolinska InstitutetStockholmSweden
  7. 7.MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton and NIHR Musculoskeletal Biomedical Research Unit, Institute of Musculoskeletal SciencesUniversity of OxfordOxfordUK
  8. 8.Hospital del Mar-IMIM-Universitat AutónomaBarcelonaSpain
  9. 9.Academic Unit of Bone Metabolism, University of Sheffield and NIHR Musculoskeletal Biomedical Research UnitSheffield Teaching Hospitals NHS TrustSheffieldUK
  10. 10.Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine IIIDresden Technical University Medical CenterDresdenGermany
  11. 11.Centre for Metabolic Bone Diseases (WHO Collaborating Centre)University of Sheffield Medical SchoolSheffieldUK
  12. 12.Department of EndocrinologyAarhus University HospitalAarhusDenmark
  13. 13.Russian Association on OsteoporosisYekaterinburgRussia
  14. 14.Department of Biochemistry and Experimental MedicineThe Children’s Memorial Health InstituteWarsawPoland
  15. 15.Department of RheumatologyC. Argerich HospitalBuenos AiresArgentina
  16. 16.Division of EndocrinologyCampus Bio-Medico UniversityRomeItaly
  17. 17.Division of Endocrinology and Metabolism, Department of Internal MedicineMedical University of GrazGrazAustria
  18. 18.Rheumatic Diseases Unit, Molecular Medicine Centre, Institute of Genetics and Molecular Medicine, Western General HospitalUniversity of EdinburghEdinburghUK
  19. 19.University of Sydney-Royal North Shore HospitalSt LeonardsAustralia
  20. 20.Cedars-Sinai/University of CaliforniaLos AngelesUSA
  21. 21.Investigation Group on Osteoporosis, Hospital University Insular, Bone Metabolic UnitUniversity of Las Palmas de Gran CanariaLas Palmas de Gran CanariaSpain
  22. 22.Institute of RheumatologyPragueCzech Republic
  23. 23.Faculty of Medicine 1Charles UniversityPragueCzech Republic
  24. 24.Action for Healthy BonesGrazAustria
  25. 25.International Osteoporosis FoundationNyonSwitzerland
  26. 26.Department of MedicineCambridge University Hospitals NHS Foundation TrustCambridgeUK

Personalised recommendations